Global Cancer/Tumor Profiling Market is Projected to Reach USD 8.74 Billion in 2022 from USD 5.26 Billion in 2017 at CAGR of 10.7%
DUBLIN, March 12, 2018 /PRNewswire/ --
The "Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, In-situ Hybridization, Microarray)- Forecast to 2021" report has been added to ResearchAndMarkets.com's offering.
Global Cancer/Tumor Profiling Market is Projected to Reach USD 8.74 Billion in 2022 from USD 5.26 Billion in 2017 at CAGR of 10.7%.
Growth in the cancer/tumor profiling market is driven by the increasing number of cancer cases, growing utility of biomarker in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer/tumor profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market.
In this report, the global cancer profiling market in this report is segmented by cancer type, application, technology, and region. On the basis of cancer type, the cancer type market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancer types. In 2017, the breast cancer segment is expected to account for the largest share of the global cancer/tumor profiling market. The largest share of this segment is mainly attributed to the high prevalence of breast cancer over the last few years, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.
North America is expected to account for the largest share of the cancer/tumor profiling market in 2017. Asia Pacific is estimated to witness the highest growth during the forecast period. The Asia Pacific region is expected to register the highest CAGR in the forecast period. In recent years, the Asia Pacific market for cancer/tumor profiling has witnessed significant growth due to the rising incidence of cancer, increasing demand for better healthcare services in developing economies such as India and China, rising number of contract research organizations (CROs), and increasing focus of international players on emerging markets.
Major players operating in the cancer profiling market include Illumina (US), QIAGEN (Netherlands), NeoGenomics Laboratories (US), HTG Molecular Diagnostic (US), and Genomic Health (US).
Market Dynamics
Drivers
- Increasing Number of New Cancer Cases
- Increasing Utility of Biomarkers in Tumor Profiling
- Availability of Funding for Cancer Research
Restraints
- High Capital Investments And Low Benefit Ratio for Biomarkers
- Lack of Skilled Professionals And Infrastructure
Opportunities
- Point-Of-Care Diagnostic Tests
- Increasing Demand for Personalized Medicine
Challenge
- Unclear Regulatory And Reimbursement Scenario
Key Topics Covered:
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology
2.1 Market Size Estimation
2.2 Market Breakdown And Data Triangulation
2.3 Macroeconomic Factor Analysis
2.3.1 Introduction
2.3.2 Demand-Side Analysis
2.3.2.1 Healthcare Expenditure Pattern
2.3.3 Supply-Side Analysis
2.3.3.1 Number of New Product Launches
3 Executive Summary
4 Premium Insights
4.1 Cancer/Tumor Profiling: Market Overview
4.2 Geographic Analysis: Cancer/Tumor Profiling Market, By Technology (2017)
4.3 Cancer/Tumor Profiling Market, By Application
4.4 Cancer/Tumor Profiling Market, By Hybridization Technology
4.5 Geographical Snapshot of the Cancer/Tumor Profiling Market
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
6 Cancer/Tumor Profiling Market, By Technology
6.1 Introduction
6.2 Immunoassays
6.3 Hybridization
6.3.1 Pcr
6.3.2 in Situ Hybridization (Ish)
6.3.3 Dna/Rna Microarray
6.4 Next Generation Sequencing
6.5 Mass Spectrometry
6.6 Other Technologies
7 Cancer/Tumor Profiling Market, By Cancer Type
7.1 Introduction
7.2 Breast Cancer
7.3 Lung Cancer
7.4 Colorectal Cancer
7.5 Prostate Cancer
7.6 Melanoma Cancer
7.7 Others Cancer
8 Cancer/Tumor Profiling Market, By Application
8.1 Introduction
8.2 Clinical Application
8.3 Research Application
9 Cancer/Tumor Profiling Market, By Region
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.4 Asia-Pacific
9.5 Rest of the World (Row)
10 Competitive Landscape
10.1 Overview
10.2 Battle for Market Share: Product Launch Was the Key Growth Strategy Adopted By Market Players Between 2013 And 2016
10.3 Product Launches
10.4 Agreements, Collaborations, And Partnerships
10.5 Acquisitions
10.6 Others Strategies
11 Company Profiles
- Caris Life Sciences
- Genomic Health Inc.
- Helomics Corporation
- Htg Molecular Diagnostics, Inc.
- Illumina, Inc.
- Nanostring Technologies, Inc.
- Neogenomics Laboratories, Inc.
- Oxford Gene Technology
- Qiagen N.V.
- Ribomed Biotechnologies, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/psvl5q/global?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article